S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
pixel
Musk says Twitter deal could move ahead with 'bot' info
Demand for grocery delivery cools as food costs rise
Dems' climate, energy, tax bill clears initial Senate hurdle
Shift in war's front seen as ships cleared to leave Ukraine
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
pixel
Musk says Twitter deal could move ahead with 'bot' info
Demand for grocery delivery cools as food costs rise
Dems' climate, energy, tax bill clears initial Senate hurdle
Shift in war's front seen as ships cleared to leave Ukraine
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
pixel
Musk says Twitter deal could move ahead with 'bot' info
Demand for grocery delivery cools as food costs rise
Dems' climate, energy, tax bill clears initial Senate hurdle
Shift in war's front seen as ships cleared to leave Ukraine
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
pixel
Musk says Twitter deal could move ahead with 'bot' info
Demand for grocery delivery cools as food costs rise
Dems' climate, energy, tax bill clears initial Senate hurdle
Shift in war's front seen as ships cleared to leave Ukraine
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
NASDAQ:RARE

Ultragenyx Pharmaceutical (RARE) Stock Forecast, Price & News

$55.60
-0.17 (-0.30%)
(As of 08/5/2022 12:00 AM ET)
Add
Compare
Today's Range
$54.29
$56.42
50-Day Range
$46.14
$66.14
52-Week Range
$45.20
$104.38
Volume
677,727 shs
Average Volume
832,705 shs
Market Capitalization
$3.89 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$112.67

Ultragenyx Pharmaceutical MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
102.6% Upside
$112.67 Price Target
Short Interest
Bearish
4.63% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.28
Upright™ Environmental Score
News Sentiment
0.00mentions of Ultragenyx Pharmaceutical in the last 14 days
Based on 18 Articles This Week
Insider Trading
Selling Shares
$16,160 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($7.79) to ($6.54) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.17 out of 5 stars

Medical Sector

487th out of 1,283 stocks

Pharmaceutical Preparations Industry

229th out of 615 stocks

Ultragenyx Pharmaceutical logo

About Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.

Ultragenyx Pharmaceutical Price Performance

Shares of NASDAQ:RARE traded down $0.17 on Friday, hitting $55.60. 677,727 shares of the company's stock were exchanged, compared to its average volume of 832,705. Ultragenyx Pharmaceutical has a 12 month low of $45.20 and a 12 month high of $104.38. The stock has a market capitalization of $3.89 billion, a price-to-earnings ratio of -7.60 and a beta of 1.21. The business's 50 day simple moving average is $55.66 and its two-hundred day simple moving average is $63.38.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Rating) last posted its earnings results on Thursday, July 28th. The biopharmaceutical company reported ($2.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.72) by ($0.54). Ultragenyx Pharmaceutical had a negative net margin of 151.34% and a negative return on equity of 60.76%. The company had revenue of $89.34 million during the quarter, compared to analysts' expectations of $87.33 million. During the same quarter last year, the firm earned ($1.45) EPS. Ultragenyx Pharmaceutical's revenue for the quarter was up 2.7% on a year-over-year basis. Equities analysts forecast that Ultragenyx Pharmaceutical will post -7.79 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

RARE has been the subject of several recent research reports. Citigroup reduced their target price on shares of Ultragenyx Pharmaceutical from $146.00 to $142.00 in a research note on Wednesday. Stifel Nicolaus reduced their target price on shares of Ultragenyx Pharmaceutical from $176.00 to $142.00 and set a "buy" rating for the company in a research note on Friday, July 1st. Piper Sandler reduced their target price on shares of Ultragenyx Pharmaceutical from $135.00 to $130.00 and set an "overweight" rating for the company in a research note on Thursday, July 28th. The Goldman Sachs Group reduced their target price on shares of Ultragenyx Pharmaceutical from $139.00 to $101.00 and set a "neutral" rating for the company in a research note on Tuesday, May 24th. Finally, Cowen reduced their target price on shares of Ultragenyx Pharmaceutical from $124.00 to $99.00 in a research note on Friday, May 6th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $112.67.

Receive RARE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ultragenyx Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

RARE Stock News Headlines

Analyst Ratings for Ultragenyx Pharmaceutical
What 7 Analyst Ratings Have To Say About Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Down 2.9%
Ultragenyx Pharmaceutical (NASDAQ:RARE) Trading 1.1% Higher
What 6 Analyst Ratings Have To Say About Ultragenyx Pharmaceutical
See More Headlines

Receive RARE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ultragenyx Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

RARE Company Calendar

Last Earnings
7/28/2022
Today
8/07/2022
Next Earnings (Estimated)
11/01/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RARE
Employees
1,119
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$112.67
High Stock Price Forecast
$142.00
Low Stock Price Forecast
$73.00
Forecasted Upside/Downside
+102.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
9 Analysts

Profitability

Net Income
$-454,020,000.00
Net Margins
-151.34%
Pretax Margin
-151.02%

Debt

Sales & Book Value

Annual Sales
$351.41 million
Book Value
$9.68 per share

Miscellaneous

Free Float
65,345,000
Market Cap
$3.89 billion
Optionable
Optionable
Beta
1.21














RARE Stock - Frequently Asked Questions

Should I buy or sell Ultragenyx Pharmaceutical stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ultragenyx Pharmaceutical in the last twelve months. There are currently 1 sell rating, 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Ultragenyx Pharmaceutical stock.
View analyst ratings for Ultragenyx Pharmaceutical
or view top-rated stocks.

What is Ultragenyx Pharmaceutical's stock price forecast for 2022?

9 brokers have issued 1 year target prices for Ultragenyx Pharmaceutical's stock. Their RARE stock forecasts range from $73.00 to $142.00. On average, they predict Ultragenyx Pharmaceutical's stock price to reach $112.67 in the next twelve months. This suggests a possible upside of 102.6% from the stock's current price.
View analysts' price targets for Ultragenyx Pharmaceutical
or view top-rated stocks among Wall Street analysts.

How has Ultragenyx Pharmaceutical's stock performed in 2022?

Ultragenyx Pharmaceutical's stock was trading at $84.09 at the beginning of the year. Since then, RARE stock has decreased by 33.9% and is now trading at $55.60.
View the best growth stocks for 2022 here
.

When is Ultragenyx Pharmaceutical's next earnings date?

Ultragenyx Pharmaceutical is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our earnings forecast for Ultragenyx Pharmaceutical
.

How were Ultragenyx Pharmaceutical's earnings last quarter?

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) announced its quarterly earnings data on Thursday, July, 28th. The biopharmaceutical company reported ($2.26) earnings per share for the quarter, missing the consensus estimate of ($1.72) by $0.54. The biopharmaceutical company had revenue of $89.34 million for the quarter, compared to the consensus estimate of $87.33 million. Ultragenyx Pharmaceutical had a negative trailing twelve-month return on equity of 60.76% and a negative net margin of 151.34%. The company's revenue for the quarter was up 2.7% on a year-over-year basis. During the same quarter in the previous year, the business earned ($1.45) earnings per share.

What is Emil D. Kakkis' approval rating as Ultragenyx Pharmaceutical's CEO?

41 employees have rated Ultragenyx Pharmaceutical CEO Emil D. Kakkis on Glassdoor.com. Emil D. Kakkis has an approval rating of 88% among Ultragenyx Pharmaceutical's employees.

What other stocks do shareholders of Ultragenyx Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ultragenyx Pharmaceutical investors own include Pfizer (PFE), AbbVie (ABBV), NVIDIA (NVDA), Exelixis (EXEL), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Micron Technology (MU), TG Therapeutics (TGTX), GW Pharmaceuticals (GWPH) and QUALCOMM (QCOM).

What is Ultragenyx Pharmaceutical's stock symbol?

Ultragenyx Pharmaceutical trades on the NASDAQ under the ticker symbol "RARE."

Who are Ultragenyx Pharmaceutical's major shareholders?

Ultragenyx Pharmaceutical's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include TD Asset Management Inc. (0.43%), Emerald Advisers LLC (0.29%), Emerald Mutual Fund Advisers Trust (0.24%), Pinnacle Associates Ltd. (0.19%), Mirae Asset Global Investments Co. Ltd. (0.18%) and Privium Fund Management B.V. (0.15%). Company insiders that own Ultragenyx Pharmaceutical stock include Camille L Bedrosian, Camille L Bedrosian, Clay B Siegall, Dennis Karl Huang, Emil D Kakkis, Emil D Kakkis, Erik Harris, John Richard Pinion, Karah Herdman Parschauer, Mardi Dier, Matthew K Fust, S Robson Walton, Shalini Sharp, Theodore Alan Huizenga, Thomas Richard Kassberg and William Aliski.
View institutional ownership trends for Ultragenyx Pharmaceutical
.

How do I buy shares of Ultragenyx Pharmaceutical?

Shares of RARE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ultragenyx Pharmaceutical's stock price today?

One share of RARE stock can currently be purchased for approximately $55.60.

How much money does Ultragenyx Pharmaceutical make?

Ultragenyx Pharmaceutical (NASDAQ:RARE) has a market capitalization of $3.89 billion and generates $351.41 million in revenue each year. The biopharmaceutical company earns $-454,020,000.00 in net income (profit) each year or ($7.32) on an earnings per share basis.

How many employees does Ultragenyx Pharmaceutical have?

Ultragenyx Pharmaceutical employs 1,119 workers across the globe.

How can I contact Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical's mailing address is 60 Leveroni Court, Novato CA, 94949. The official website for Ultragenyx Pharmaceutical is www.ultragenyx.com. The biopharmaceutical company can be reached via phone at (415) 483-8800, via email at ir@ultragenyx.com, or via fax at 415-483-8810.

This page (NASDAQ:RARE) was last updated on 8/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.